Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Icatolimab |
Trade Name | |
Synonyms | JS004|JS-004|JS 004|TAB004|TAB-004|TAB 004|Tifcemalimab |
Drug Descriptions |
Icatolimab (JS004) is a humanized monoclonal antibody that binds to B- and T-lymphocyte attenuator (BTLA) and activates T-cells, thereby potentially resulting in the activation of antitumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2643). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C168617 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Icatolimab | Icatolimab | 0 | 1 |
Icatolimab + Toripalimab-tpzi | Icatolimab Toripalimab-tpzi | 0 | 1 |